Dimer of molecular variant of apolipoprotein and processes for the production thereof

US6617134B1 · kind B1 · utility

Assignee

• Esperion Therapeutics, Inc. · US

Inventors

• Cesare Sirtori · Milano, IT
• Guido Franceschini · Milano, IT
• Lars Abrahmsen · Bromma, SE
• Erik Holmgren · Lidingö, SE
• Mats Lake · Lidingö, SE
• Bjorn Nilsson · Foster City, US
• Joanna Chmielewska · Stockholm, SE
• Peter Lind · Uppsala, SE

Key dates

• Filing date: Mar 1, 1999
• Grant date: Sep 9, 2003
• Expiry date: Mar 1, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.